← Leaderboards
Dong Moon Shin
University Of Pittsburgh At Pittsburgh
$11,702,631
Attributed
$13,929,953
Total exposure
11
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.1M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$25,887,838 · 12
By mechanism
P50$14,179,753 · 3
U01$5,162,751 · 2
R01$3,876,785 · 3
T32$1,175,306 · 1
U54$648,204 · 1
R21$429,000 · 1
Top collaborators
- Mostafa A El-Sayed5 shared
- Periasamy Selvaraj4 shared
- Yonggang Ke2 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Ramesh Ramanathan$303,574
Others in their field
Top investigators on “Head And Neck Cancer”
- Walter John Curran · Thomas Jefferson University$111,090,486
- Norman Wolmark · Nsabp Foundation, Inc.$59,047,729
- David Heimbrook · Leidos Biomedical Research, Inc.$56,561,099
- Robert S Mannel · University Of Oklahoma Hlth Sciences Ctr$42,566,636
- Charles A Coltman · Southwest Oncology Group$36,988,659
- James J. Dignam · University Of Chicago$35,003,821
Research focus
Head And Neck CancerMalignant NeoplasmsHead And Neck Squamous Cell CarcinomaIn VitroToxic EffectCancer TherapyClinical TrialsClinical ResearchProgramsIn VivoDrug KineticsSafetyEpidermal Growth Factor ReceptorChemopreventionCellsMediatingTumorPreventResponseApoptosisPathway InteractionsResearch PersonnelCell LinePre-Clinical
Grant awards (49)
Personalized vaccine immunotherapy in combination with anti-PD 1 antibody for recurrent or metastatic squamous cell carcinoma of the head and neck$629,482
R01 · FY2025 · CA · contact PI
Personalized vaccine immunotherapy in combination with anti-PD 1 antibody for recurrent or metastatic squamous cell carcinoma of the head and neck$639,614
R01 · FY2024 · CA · contact PI
Personalized vaccine immunotherapy in combination with anti-PD 1 antibody for recurrent or metastatic squamous cell carcinoma of the head and neck$48,916
R01 · FY2024 · CA · contact PI
Personalized vaccine immunotherapy in combination with anti-PD 1 antibody for recurrent or metastatic squamous cell carcinoma of the head and neck$625,507
R01 · FY2023 · CA · contact PI
Translational Physician-Scientist Training Program in Oncology$242,661
T32 · FY2017 · CA · contact PI
Therapeutic siRNA Delivery using DNA Nanoparticles (DNPs) for Cancer$195,000
R21 · FY2017 · EB · contact PI
Translational Physician-Scientist Training Program in Oncology$252,582
T32 · FY2016 · CA · contact PI
Therapeutic siRNA Delivery using DNA Nanoparticles (DNPs) for Cancer$234,000
R21 · FY2016 · EB · contact PI
Translational Physician-Scientist Training Program in Oncology$277,111
T32 · FY2015 · CA · contact PI
Toxicity and Efficacy of Gold Nanoparticle Photothermal Therapy in Cancer$377,136
U01 · FY2014 · CA · contact PI
Translational Physician-Scientist Training Program in Oncology$272,419
T32 · FY2014 · CA · contact PI
Toxicity and Efficacy of Gold Nanoparticle Photothermal Therapy in Cancer$385,879
U01 · FY2013 · CA · contact PI
Translational Physician-Scientist Training Program in Oncology$130,533
T32 · FY2013 · CA · contact PI
Toxicity and Efficacy of Gold Nanoparticle Photothermal Therapy in Cancer$419,994
U01 · FY2012 · CA · contact PI
SPORE in Head and Neck Cancer$2,185,000
P50 · FY2011 · CA · contact PI
Toxicity and Efficacy of Gold Nanoparticle Photothermal Therapy in Cancer$430,117
U01 · FY2011 · CA · contact PI
CHEMOPREVENTION WITH GREEN TEA POLYPHENON E (PPE) AND EGFR-TKIs IN HEAD AND NECK$385,804
P50 · FY2011 · CA · contact PI
Second Primary Tumor Prevention w/EGFR TKIs, COX-2 inhibitors Head & Neck Cancer$316,876
R01 · FY2011 · CA · contact PI
SPORE in Head and Neck Cancer$2,300,000
P50 · FY2010 · CA · contact PI
Toxicity and Efficacy of Gold Nanoparticle Photothermal Therapy in Cancer$469,000
U01 · FY2010 · CA · contact PI
CHEMOPREVENTION WITH GREEN TEA POLYPHENON E (PPE) AND EGFR-TKIs IN HEAD AND NECK$434,450
P50 · FY2010 · CA · contact PI
SPORE in Head and Neck Cancer$200,000
P50 · FY2010 · CA · contact PI
SPORE in Head and Neck Cancer$2,300,000
P50 · FY2009 · CA · contact PI
CHEMOPREVENTION WITH GREEN TEA POLYPHENON E (PPE) AND EGFR-TKIs IN HEAD AND NECK$418,207
P50 · FY2009 · CA · contact PI
Nanotherapeutics: Multifunctional Nanoparticles for Drug Delivery and Targeting$367,451
U54 · FY2009 · CA · contact PI
Second Primary Tumor Prevention w/EGFR TKIs, COX-2 inhibitors Head & Neck Cancer$328,776
R01 · FY2009 · CA · contact PI
SPORE in Head and Neck Cancer$200,000
P50 · FY2009 · CA · contact PI
SPORE in Head and Neck Cancer$2,272,885
P50 · FY2008 · CA · contact PI
Chemoprevention of Head and Neck Cancer with ZD1839 and Celecoxib$618,139
U01 · FY2008 · CA · contact PI
CHEMOPREVENTION WITH GREEN TEA POLYPHENON E (PPE) AND EGFR-TKIs IN HEAD AND NECK$415,587
P50 · FY2008 · CA · contact PI
Second Primary Tumor Prevention w/EGFR TKIs, COX-2 inhibitors Head & Neck Cancer$321,301
R01 · FY2008 · CA · contact PI
Nanotherapeutics: Multifunctional Nanoparticles for Drug Delivery and Targeting$280,753
U54 · FY2008 · CA · contact PI
SPORE in Head and Neck Cancer$200,000
P50 · FY2008 · CA · contact PI
SPORE in Head and Neck Cancer$2,300,000
P50 · FY2007 · CA · contact PI
Chemoprevention of Head and Neck Cancer with ZD1839 and Celecoxib$603,423
U01 · FY2007 · CA · contact PI
CHEMOPREVENTION WITH GREEN TEA POLYPHENON E (PPE) AND EGFR-TKIs IN HEAD AND NECK$391,274
P50 · FY2007 · CA · contact PI
Second Primary Tumor Prevention w/EGFR TKIs, COX-2 inhibitors Head & Neck Cancer$320,257
R01 · FY2007 · CA · contact PI
ADMINISTRATION CORE$176,546
P50 · FY2007 · CA · contact PI
Chemoprevention of the Head and Neck Cancer with ZD1839*$609,876
U01 · FY2006 · CA · contact PI
Second Primary Tumor Prevention w/EGFR TKIs & COX-2 inhibitors in H & N Cancer$334,774
R01 · FY2006 · CA · contact PI
CORE--CLINICAL SUPPORT/BIOSTATISTICS$88,198
P01 · FY2006 · DE · contact PI
Chemoprevention of the Head and Neck Cancer with ZD1839*$611,705
U01 · FY2005 · CA
CORE--CLINICAL SUPPORT/BIOSTATISTICS$85,629
P01 · FY2005 · DE
Chemoprevention of Head and Neck Cancer$637,482
U01 · FY2004 · CA
CORE--CLINICAL SUPPORT/BIOSTATISTICS$83,135
P01 · FY2004 · DE
CORE--CLINICAL SUPPORT/BIOSTATISTICS$80,714
P01 · FY2003 · DE
CORE--CLINICAL SUPPORT/BIOSTATISTICS$78,363
P01 · FY2002 · DE
RANDOMIZED ADJUVANT THERAPY OF HEAD AND NECK CANCER$158,621
R01 · FY2001 · CA
RANDOMIZED ADJUVANT THERAPY OF HEAD AND NECK CANCER$152,661
R01 · FY2000 · CA